Table 1.
Baseline characteristics of cohort of interest in the COVID-19 Research Network.
| Category | Sub-Category | Patients, n = 238 (%) |
|---|---|---|
| Sex | Male | 148 (62%) |
| Female | 78 (33%) | |
| Unknown | 12 (5%) | |
| Ethnicity | Not Hispanic or Latino | 72 (30%) |
| Hispanic or Latino | 10* (4%) | |
| Unknown | 159 (66%) | |
| Race | White | 65 (27%) |
| Black or African American | 11 (4%) | |
| Asian | 10* (4%) | |
| Native Hawaiian or other | 10* (4%) | |
| Other | 10* (4%) | |
| Unknown | 154 (64%) | |
| Age at index (years) | Mean | 61.2 |
| Standard deviation | 15.5 | |
| Minimum | 18 | |
| Maximum | 87 | |
| COVID-19 diagnosis | 173 (73%) | |
| Overweight, obesity, and other hyperalimentation | 31 (13%) | |
| Essential (primary) hypertension | 82 (34%) | |
| Diabetes mellitus | 39 (16%) | |
| Chronic lower respiratory diseases | 35 (15%) | |
| Other chronic obstructive pulmonary disease | 16 (7%) | |
| Nicotine dependence | 14 (6%) | |
| Heart diseases | Ischemic heart diseases | 19 (8%) |
| Other forms of heart disease | 47 (20%) | |
| Acute kidney failure and chronic kidney disease | 60 (25%) | |
| Chronic kidney disease | 34 (14%) | |
| Diseases of liver | 16 (7%) | |
| Neoplasms | 49 (21%) | |
| Malignant neoplasms of lymphoid, hematopoietic, and related tissue | 22 (9%) | |
| Certain disorders involving the immune mechanism | 24 (10%) | |
| Antivirals | 114 (48%) | |
| Lopinavir | 88 (37%) | |
| Ritonavir | 88 (37%) | |
| Respiratory tract medications | 109 (46%) | |
| Hydroxychloroquine | 99 (42%) | |
| Immunological agents | 25 (11%) |
* To protect patient privacy, the minimum number of patients shown in TriNetX is 10.